Sugi Predict

Sugi Predict / Compounds / SCHEMBL16338682

SCHEMBL16338682

SCHEMBL16338682

C[C@@H]1CC(=O)C[C@@H](C)N1C(=O)OC(C)(C)C

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ CHRM2 P08172 1/20 0.47
▸ CHRM1 P11229 1/20 0.47
▸ CHRM3 P20309 1/20 0.47
▸ PREP P48147 3/20 0.39
▸ USP2 O75604 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ THRB P10828 1/20 0.37
▸ HSD11B1 P28845 1/20 0.37
▸ NR1H2 P55055 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ HPGD P15428 1/20 0.36
▸ ABCB1 P08183 1/20 0.35
▸ GPR119 Q8TDV5 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13096648 1.00 CHRM2 (0.47) CHRM2CHRM1CHRM3PREPUSP2
SCHEMBL15700445 1.00 CHRM2 (0.47) CHRM2CHRM1CHRM3PREPUSP2
SCHEMBL15188280 1.00 CHRM2 (0.47) CHRM2CHRM1CHRM3PREPUSP2
SCHEMBL9885648 1.00 CHRM2 (0.47) CHRM2CHRM1CHRM3PREPUSP2
SCHEMBL756839 1.00 CHRM2 (0.47) CHRM2CHRM1CHRM3PREPUSP2
SCHEMBL24212059 0.85 CHRM2 (0.40) CHRM2CHRM1CHRM3PREPKDM4E
SCHEMBL13845952 0.85 CHRM2 (0.40) CHRM2CHRM1CHRM3PREPKDM4E
SCHEMBL21064056 0.85 CHRM2 (0.40) CHRM2CHRM1CHRM3PREPKDM4E
SCHEMBL31699337 0.85 NR1H2 (0.40) CHRM2CHRM1CHRM3PREPKDM4E
SCHEMBL20307686 0.84 CHRM2 (0.39) CHRM2CHRM1CHRM3PREPUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025101780-A1 PHARMACOLOGICAL CORRECTORS OF RHODOPSIN AND USES THEREOF OCTANT, INC. (US) 2025-05-15 — — WO disclosed
WO-2025069270-A1 AZAINDOLE COMPOUND AND MEDICINE 日本新薬株式会社 2025-04-03 — — WO disclosed
WO-2025070627-A1 AZAINDOLE COMPOUND AND MEDICAL DRUG 日本新薬株式会社 2025-04-03 — — WO disclosed
US-20240391931-A1 TRICYCLIC FUSED PYRIMIDINE COMPOUNDS FOR USE AS HER2 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2024-11-28 — — US disclosed
US-20240165121-A1 SUBSTITUTED BENZENE COMPOUNDS EPIZYME INC (US) 2024-05-23 — — US disclosed
CN-117980309-A Tricyclic fused pyrimidine compounds useful as HER2 inhibitors 百时美施贵宝公司 2024-05-03 — — CN disclosed
US-20240067646-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY HOFFMANN-LA ROCHE INC. 2024-02-29 — — US disclosed
US-11753407-B2 Compounds for treating spinal muscular atrophy PTC THERAPEUTICS, INC. (US) 2023-09-12 — — US disclosed
US-11642348-B2 Substituted benzene compounds Epizyme, Inc. (US) 2023-05-09 — — US disclosed
US-11642348-B2 Substituted benzene compounds Epizyme, Inc. (US) 2023-05-09 — — US disclosed
US-10092572-B2 Substituted benzene compounds Epizyme, Inc. (US) 2018-10-09 — — US disclosed
EP-2812004-B1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC THERAPEUTICS INC (US) 2018-06-27 — — EP disclosed
US-20180105526-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC THERAPEUTICS INC (US) 2018-04-19 — — US disclosed
US-9879007-B2 Compounds for treating spinal muscular atrophy PTC THERAPEUTICS, INC. (US) 2018-01-30 — — US disclosed
US-20170129885-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY HOFFMANN-LA ROCHE INC. 2017-05-11 — — US disclosed
US-9586955-B2 Compounds for treating spinal muscular atrophy PTC THERAPEUTICS, INC. (US) 2017-03-07 — — US disclosed
US-20150284370-A1 SUBSTITUTED BENZENE COMPOUNDS Epizyme, Inc. 2015-10-08 — — US disclosed
US-20150284370-A1 SUBSTITUTED BENZENE COMPOUNDS Epizyme, Inc. 2015-10-08 — — US disclosed
US-20150284370-A1 SUBSTITUTED BENZENE COMPOUNDS Epizyme, Inc. 2015-10-08 — — US disclosed
US-20150005289-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY HOFFMANN-LA ROCHE INC. 2015-01-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240067646-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY SMN1; SMN2, CPT1B, GYS1 CHRM2 2327/4885CHRM1 3391/4885CHRM3 2370/4885
US-20240391931-A1 TRICYCLIC FUSED PYRIMIDINE COMPOUNDS FOR USE AS HER2 INHIBITORS ERBB2, ERBB3, EGFR CHRM2 4465/4885CHRM1 4783/4885CHRM3 4317/4885
US-20150284370-A1 SUBSTITUTED BENZENE COMPOUNDS CYP1B1, TP53, VHL CHRM2 4165/4885CHRM1 4513/4885CHRM3 3392/4885
US-20150005289-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY SMN1; SMN2, CPT1B, GYS1 CHRM2 2496/4885CHRM1 3575/4885CHRM3 1981/4885
US-10092572-B2 Substituted benzene compounds CYP1B1, TP53, VHL CHRM2 4165/4885CHRM1 4513/4885CHRM3 3392/4885
US-20180105526-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY SMN1; SMN2, CPT1B, GYS1 CHRM2 2496/4885CHRM1 3575/4885CHRM3 1981/4885
US-20240165121-A1 SUBSTITUTED BENZENE COMPOUNDS CYP1B1, TP53, VHL CHRM2 4165/4885CHRM1 4513/4885CHRM3 3392/4885
US-20170129885-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY SMN1; SMN2, CPT1B, GYS1 CHRM2 2496/4885CHRM1 3575/4885CHRM3 1981/4885
US-11753407-B2 Compounds for treating spinal muscular atrophy SMN1; SMN2, CPT1B, GYS1 CHRM2 1045/4885CHRM1 1881/4885CHRM3 1485/4885
US-11642348-B2 Substituted benzene compounds CYP1B1, TP53, VHL CHRM2 4165/4885CHRM1 4513/4885CHRM3 3392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.